Product Information
GABARONE 400 MG TABLET is a brand (anda) product labeled by INA Pharmaceutics Inc., priced at $8.5711 per EA under NDC 74157011190. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Mar 4, 2024. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
400 mg/1
Manufacturer
INA Pharmaceutics Inc.NDC
74157011190
Classification
Brand (ANDA)
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA211313FDA Approved
3/4/2024
TE Code
AB1
On Market Since
12/23/2024
Pharmacological Classes
Price Statistics
The NADAC for GABARONE 400 MG TABLET has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.5711 per EA |
|---|---|
| All-time high | $8.5711 (Sep 30, 2026) |
| All-time low | $8.3259 (May 20, 2026) |
| 52-week high | $8.5711 |
| 52-week low | $8.3259 |
| Median price | $8.5689 |
| Average price | $8.4736 |
| Largest weekly change | +2.9% (Aug 19, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Gabapentin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
INA Pharmaceutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABARONE 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GABARONE 400 MG TABLET, manufactured by INA Pharmaceutics Inc., is $8.5711 per EA (NDC 74157011190), effective Sep 30, 2026.
How has the price of GABARONE 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for GABARONE 400 MG TABLET has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for GABARONE 400 MG TABLET?
Since Feb 18, 2026, the NADAC for GABARONE 400 MG TABLET has ranged from a low of $8.3259 (May 20, 2026) to a high of $8.5711 (Sep 30, 2026), with a median of $8.5689 per EA.
Are there cheaper alternatives to GABARONE 400 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of GABARONE 400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GABARONE 400 MG TABLET?
GABARONE 400 MG TABLET (NDC 74157011190) is labeled by INA Pharmaceutics Inc., and CMS classifies it as a brand (anda) product.